Lv41
446 积分 2025-01-03 加入
Adjusted significance levels for subgroup analyses in clinical trials
1个月前
已完结
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
1个月前
已完结
Adjusted significance levels for subgroup analyses in clinical trials
1个月前
已关闭
Designing Issues in Confirmatory Adaptive Population Enrichment Trials
1个月前
已完结
A graphical approach to sequentially rejective multiple test procedures
3个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
4个月前
已关闭
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
5个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
7个月前
已完结
TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS
7个月前
已完结
皖公网安备34019202002308
